What Can We Expect From Abbott’s Q2’16 Earnings?
Abbott Laboratories (NYSE:ABT) is set to announce its Q2’16 earnings on July 20th. In Q1’16, despite a strong operating growth, the company’s key metrics declined due to currency headwinds. Abbott’s net income and EPS figures were significantly affected by the write down of its assets in Venezuela. However, the asset write down was likely a one time thing and the foreign currency headwinds might have eased in Q2. Moreover, Abbott had raised its annual guidance in the last earnings call because it expected currency gains across all of its segments going ahead. Furthermore, in Q2 the company received the FDA approval for its Absorb stent – the first bioresorbable stent to cure coronary artery disease. Given the large number of people suffering from the coronary heart disease, we believe that Abbott has a significant opportunity to improve its revenue from the vascular segment going forward. Below we look at the key metrics as expected for the company in Q2’16:
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
- What’s Next For Abbott Stock After A 6% Rise This Year?
- Is Abbott Stock Undervalued At $95?
- Which Is A Better Pick – Abbott Stock Or Amgen?
- Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
- Lower Testing Demand To Weigh On Abbott’s Q2?
- Will Abbott Stock Rebound To Its 2022 Highs?